For research use only. Not for therapeutic Use.
DDO-2093 dihydrochloride is a potent MLL1-WDR5 protein-protein interaction inhibitor (IC50=8.6 nM; Kd=11.6 nM) with antitumor activity. DDO-2093 dihydrochloride selectively inhibits the catalytic activity of MLL complex[1].
DDO-2093 (5 μM; pretreated 7 days) dihydrochloride inhibits MLL-fusion protein dependent genes expression (HOXA9 and Meis1)[1].
DDO-2093 (20-80 mg/kg; i.p.; every other day for 21 days) dihydrochloride significantly suppresses the tumor size and weight in a dose-dependent manner[1].
| Catalog Number | I042712 |
| Synonyms | 1-[3-[(5-amino-2-chloro-4-fluoro-3-methylbenzoyl)amino]-4-(4-methylpiperazin-1-yl)phenyl]-N-(3-morpholin-4-ylpropyl)triazole-4-carboxamide;dihydrochloride |
| Molecular Formula | C29H39Cl3FN9O3 |
| Purity | ≥95% |
| InChI | InChI=1S/C29H37ClFN9O3.2ClH/c1-19-26(30)21(17-22(32)27(19)31)28(41)34-23-16-20(4-5-25(23)39-10-8-37(2)9-11-39)40-18-24(35-36-40)29(42)33-6-3-7-38-12-14-43-15-13-38;;/h4-5,16-18H,3,6-15,32H2,1-2H3,(H,33,42)(H,34,41);2*1H |
| InChIKey | RIMZKQNHTPMNER-UHFFFAOYSA-N |
| SMILES | CC1=C(C(=CC(=C1F)N)C(=O)NC2=C(C=CC(=C2)N3C=C(N=N3)C(=O)NCCCN4CCOCC4)N5CCN(CC5)C)Cl.Cl.Cl |
| Reference | [1]. Chen W, et al. Discovery of a potent MLL1 and WDR5 protein-protein interaction inhibitor with in vivo antitumor activity [published online ahead of print, 2021 Jun 28]. Eur J Med Chem. 2021;223:113677. |
